Top Tech Companies (2,070)
Don't see your company?
Create a company profile
Conceptual MindWorks, Inc. (CMI) is a diversified basic and applied research, consulting, and software engineering company with over 23 years of providing health-related software, bioinformatics, biotechnology, scientific, and technical solutions to the public and private sectors.
Veru improve lives through innovative science and medicine as a leading biopharmaceutical company focused on urology and oncology.
Biora Therapeutics is reimagining therapeutics by creating smart pills designed for - targeted drug delivery to the GI tract, and - systemic, needle-free delivery of biotherapeutics we are developing therapies to improve patients’ lives. At Biora, we envision a world where patients have access to needle-free drug delivery and better therapeutic outcomes. We welcome you to learn more about our mission and our guiding principles at https://bioratherapeutics.com/company/about
Allevi builds tools to design and engineer with life. Our 3D bioprinters and bioinks are used by leading researchers worldwide to find solutions to humanity's most difficult problems - to cure disease, to test novel drugs, to eliminate the organ waiting list, to build with life. Founded in 2014, our mission is to make it easy to design and engineer 3D tissues. We created our desktop 3D bioprinter to be the most versatile, powerful and easy-to-use bioprinter on the market. Since our humble beginnings, we have grown to serve hundreds of labs in all corners of the world and have become leaders in the biofabrication revolution. Allevi 3D bioprinters, software, and bioinks print 3D living tissues one layer at a time. We are constantly inspired by our community of users who are performing world-class research on our platform. When your work has life-changing implications for people all over the world, it’s an amazing responsibility. That ingenuity. That importance. That’s Allevi. We believe everyone has the potential to change the course of medicine.
VisionGate, Inc., is a breakthrough liquid-biopsy technology company, leading the battle against lung cancer through early detection technology with a simple, non-intrusive sputum test. The foundation for our diagnostics capability is the proprietary Cell-CT™ 3-Dimensional Cell Imaging and Analysis platform. The Cell-CT platform, using a process called optical computed tomography (CT), produces 3D images of individual cells with the ability to morphologically recognize over 700 structural biomarkers of normal and abnormal cells. The Cell-CT platform can process any liquid biopsy specimen and therefore has potential applicability to detect a wide range of different cancers and cancer biosignatures that could aid in identifying potential treatments using targeted pharmaceutical therapies. Our lead diagnostic product is the LuCED® lung test - a non-invasive sputum-based test that detects abnormal cells which indicate lung cancer and bronchial dysplasia. LuCED lung test utilizes the Cell-CT platform and is in development for the early detection of lung cancer, bronchial dysplasia and the assessment of indeterminate pulmonary nodules (IPN). The LuCED test includes CellGazer™ application, an imaging software tool under development to facilitate cytopathology diagnosis of abnormal cell images detected by the Cell-CT platform. Visit www.visiongate3d.com to learn more.
Luminary Therapeutic is a cancer research center focus on helping more patients faster.
Avid Radiopharmaceuticals develops molecular imaging agents for detecting and monitoring chronic human diseases.
Navigate BioPharma Services, Inc.,* delivers high quality, innovative and differentiated solutions for drug development and diagnostic applications. As a trusted partner, we support custom assay development and end-to-end clinical trial testing from sample logistics to project and data management for global clinical trials. Our broad portfolio of diverse technologies for clinical biomarker and diagnostic applications are run by specialized professionals experienced in GxP, CAP and CLIA requirements. *Navigate BioPharma is an independent subsidiary of Novartis.
Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer. Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.
AsclepiX Therapeutics is a biotech company that develops novel therapeutics to revolutionize the treatment of retinal diseases and cancer.
We are a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. Our natural solutions play a key role in creating a food system that is resilient and prepared to feed a growing population while also minimizing its adverse climate impact – ensuring greater sustainability from farm to fork. Our product innovation is based on almost 40,000 microbial strains – we like to refer to them as ‘good bacteria’. With the offset in our microbial platform, we are uniquely positioned to address some of society’s most pressing challenges such as climate change, food waste, global health and the overuse of antibiotics and pesticides. Developing sustainable solutions is an integral part of Chr. Hansen’s quest to grow a better world naturally. The UN Sustainable Development Goals are an integrated part of our corporate strategy, focusing on goal 2, 3 and 12 related to zero hunger, good health and responsible consumption and production. In fact, 81% of our revenue directly supports these goals. In a commitment to curb climate change and limit the global temperature rise, Chr. Hansen has joined the Science Based Targets initiative to limit the global temperature rise, and commits to set ambitious carbon emission reduction targets. We are humbled and proud that Chr. Hansen several times has been recognized as a global sustainability leader. For five consecutive years (2018 – 2022) Chr. Hansen has been listed on Corporate Knights’ list of the Global 100 Most Sustainable Corporations. The inclusion on the list was cemented in 2019, 2020 and 2022 when we were ranked respectively no. 1, 2 and 2. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 145 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Let’s grow a better world. Naturally.
Twenty years ago, we pioneered the world's first clear aligners. Since then, we have continuously innovated with new products and technologies that are revolutionizing treatments for doctors and their patients. Invisalign clear aligners and the iTero Intraoral scanner help dental professionals achieve the clinical results they expect and deliver effective, advanced dental options to their patients. Helping change millions of lives, one smile at a time. Discover your straight path to a bright future at Align. As a part of our smart, diverse and fast-moving global team, you'll make an impact for the market leader that's moving an industry forward. Want to find out what’s next for us—and for you?
Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology and infectious diseases. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology and infectious diseases, including COVID-19. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, Berlin and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.
Lumos Diagnostics (ASX:LDX) specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.
AlivaMab Discovery Services is a leader in the discovery of antibody therapeutics, trusted by top-tier pharmaceutical and biotechnology companies to deliver panels of drug-quality human antibodies. We meet our partners' design goals, from simple to extraordinarily challenging, through rapid generation of large, molecularly diverse panels of antibodies with deep functional and kinetic characterization, developability assessment and state of the art engineering approaches. Combining collaborative access to our scientists' creativity and experience with the use of trusted, proven technologies, AlivaMab Discovery Services provides the fastest and most de-risked path through discovery and development.
Personalized health and wellness programs based on human behavior research.
GenPrime provides microbial detection and diagnostic analysis technology solutions.
DCN Dx specializes in contract development of rapid point of care tests. We offer a variety of services and products that assist our clients in the design and development of user-centric, high performing diagnostic devices. Contract development of rapid immunoassays is at the core of all that we do at DCN Dx. We focus on lateral flow, flow through, and microfuidic formats. Our staff has unparalleled experience in developing assays with tough specifications, regarding high sensitivity, quantification, multiplexing and reader integration. Our ISO 9001:2015 compliant development process allows for close integration of assay and device development pathways, which ensures the best chance of commercial success for the product. As well as developing the assay itself, DCN Dx's integrated engineering team will design, develop and integrate your entire device. The engineers work closely with our scientists to create cassettes and sample handling devices that enhance the performance of your assay and meet all end-user specifications. We deliver the product, not just the parts. DCN Dx also offers a variety of products and services to assist our clients at any stage of development, including: - Custom, private education and training courses in lateral flow technology, during which we teach the details of how to develop and manufacture rapid assays. - Consulting services to assist with any aspect of rapid assay development, manufacturing, regulation and commercialization. - Custom protein-protein, protein-particle, small molecule-protein and small molecule- particle conjugations. - Lateral flow material starter kits, conjugation kits, reagents, cassettes and materials for use during rapid assay development. DCN Dx represents a single source that can help you manage and deliver completely validated assay platforms. CONTACT US: www.dcndx.com [email protected] (760) 804-3886
Carmell Therapeutics Corporation is a privately-owned biotechnology company focused on the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs). These PBMs contain a concentration of natural regenerative factors that promote healing, reduce complications, and lead to healthcare savings.
Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another in-licensed from the University of Oxford targeting cone-rod dystrophy (CRD), an inherited retinal disease. Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. The Company is supported by funds from Syncona and additional investors including Oxford Science Enterprises. Find out more about us online at: www.beacontx.com.
